Figure 2.
Nilotinib Enhanced Valvular Interstitial Cell Calcification and Osteogenic Signaling
Treatment of human valvular interstitial cells with nilotinib increased phosphate-induced calcification after 9 days and mRNA expression of the osteogenic activator bone morphogenic protein (BMP)-2 after 24 h. In contrast, treatment with imatinib was not significantly different from vehicle control (dimethyl sulfoxide). Data represented as mean ± SD. **p < 0.01; ***p < 0.001.